Role of PCSK9 Inhibitors in Contemporary Lipid-Lowering Era: A Systematic Review of LDL-C Reduction, Cardiovascular Outcomes, and Use in Statin-Intolerant and Very-High-Risk Patients

Authors

  • Deepak Sabharwal
  • Iana Malasevskaia

DOI:

https://doi.org/10.56570/hkdzy418

Keywords:

PCSK9 inhibitors, LDL cholesterol, hypercholesterolemia, cardiovascular disease, statin intolerance, lipid management, evolocumab, alirocumab

Abstract

inhibitors have expanded lipid-lowering options for patients who do not achieve low-density lipoprotein cholesterol (LDL-C) targets with standard therapy or who are unable to tolerate statins. Their role in cardiovascular risk reduction continues to evolve as outcome data accumulate and clinical experience grows.

References

Downloads

Published

2026-04-01

Issue

Vol. 5 No. 1 (2026): Vol 5 Issues 1 (2026)

Section

Articles

How to Cite

1.
Deepak Sabharwal, Iana Malasevskaia. Role of PCSK9 Inhibitors in Contemporary Lipid-Lowering Era: A Systematic Review of LDL-C Reduction, Cardiovascular Outcomes, and Use in Statin-Intolerant and Very-High-Risk Patients. Journal For International Medical Graduates. 2026;5(1). doi:10.56570/hkdzy418